1 / 32

Surgical Management of Valvular Heart Disease

Surgical Management of Valvular Heart Disease. Current Treatment and Future Trends. Anthony J. Palazzo, M.D.F.A.C.S. Objectives. Brief discussion of most common pathologic valvular disease involving aortic and mitral valves Focus on aortic stenosis and mitral regurgitation

celina
Download Presentation

Surgical Management of Valvular Heart Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Surgical Management of Valvular Heart Disease Current Treatment and Future Trends Anthony J. Palazzo, M.D.F.A.C.S.

  2. Objectives • Brief discussion of most common pathologic valvular disease involving aortic and mitral valves • Focus on aortic stenosis and mitral regurgitation • Indications for surgical intervention • Best choice of prosthetic device • Current and future trends

  3. Aortic Stenosis • Etiology • Degenerative (Calcification) • Bicuspid • Rheumatic

  4. Aortic Stenosis - Classification Normal Aortic Valve Area 2-4 cm²

  5. Aortic Stenosis-Pathophysiology • Increased transvalvular gradient • Increased left ventricular afterload • Leads to development of LVH

  6. Aortic Stenosis-Natural History • Multiple echocardiographic studies have demonstrated that the average rate of decrease in aortic valve area is approximately 0.12 cm² per year • Ross and Braunwald study (1968)- landmark paper revealing natural history as it relates to symptoms • average survival with angina/syncope 3 yrs • average survival with dyspnea 2 yrs • average survival with CHF 1.5 yrs

  7. Aortic Stenosis-Natural History • Loma Lima study • Retrospective review of 453 patients with documented severe aortic stenosis on ECHO • Treated non-surgically • Survival at 1, 5, and 10 years was 62%, 32% and 18% • Demonstrated grave prognosis of patients with severe aortic stenosis • AnnThorSurg, 2006

  8. Aortic Stenosis-Indications for Surgery • Patients with symptoms • Asymptomatic patients with evidence of diminished left ventricular function (EF < 50%) • Asymptomatic patients with normal ventricular function should be followed closely with serial echocardiography every 6 months due to known history of progression of 0.1-0.12 cm² and risk of death of 1-3% per year

  9. Aortic Stenosis-Salient Points • Once diagnosis is suspected echocardiogram is single best non-invasive diagnostic test to determine aortic valve morphology, gradient and jet velocity • Symptomatic patients should be referred for surgical evaluation • Asymptomatic patients need to be followed closely for natural progression of disease • Asymptomatic patients with diminished left ventricular function should be referred for surgery

  10. Aortic Regurgitation-Etiology • Calcific degeneration (mixed lesion with stenosis) • Bicuspid aortic valve • Connective tissue disease (Marfan’s) • Aortic aneursym • Aortic dissection • Endocarditis

  11. Aortic Regurgitation-Pathophysiology • Increased left ventricular overload • Left ventricular dilatation • Diminishing left ventricular function

  12. Aortic Regurgitation-Indications for Surgery • Symptomatic patients with severe aortic regurgitation patients with angina have >10% mortality/year >20% mortality/year with CHF • Endocarditis with hemodynamic decompensation • Asymptomatic patients •surgery for patients with EF <50% •surgery for patients with evidence of left ventricular distension (end-diastolic dimension > 75 mm and end-systolic dimension > 55 m)

  13. Mitral Stenosis • Normal mitral valve area 4-6 cm² • Rheumatic heart disease most common cause • prevalence decreased significantly • Thickening and calcification of leaflets • Thickening of subvalvular structures (chords) • May have mixed lesions-MS/MR • Stenosis tends to progress slowly

  14. Mitral Stenosis-Classification Normal mitral valve area = 4-6 cm²

  15. Mitral Stenosis-Indications for Surgery • Patients with severe mitral stenosis with class NYHA class III and IV symptoms who are not candidates for percutaneous balloon mitral valvulotomy (patients with mixed lesions or heavy calcification) • Asymptomatic patients with severe MS and severe pulmonary hypertension (PAP > 60 mm Hg) • No therapy recommended in asymptomatic patients without evidence of severe pulmonary hypertension

  16. Mitral Regurgitation-Etiology • Degenerative “myxomatous” isolated leaflet prolapse Barlow’s disease • Ischemic acute- ruptured papillary muscle/chord 2° AMI chronic- chronic myocardial ischemia • Endocarditis

  17. Mitral Regurgitation-Etiology • Isolated “P-2” segmental prolapse

  18. Mitral Regurgitation-Etiology Barlow’s disease

  19. Ischemic Mitral Regurgitation Chronic ischemic mitral regurgitation annular dilatation papillary muscle retraction

  20. Mitral Regurgitation-Diagnosis • ECHO most informative non-invasive diagnostic test • Assess leaflet morphology • Chordal rupture • Leaflet prolapse • Regurgitant jets • Ejection fraction

  21. Mitral Regurgitation-Indications for Surgery (Class I indications) • Symptomatic acute mitral regurgitation ruptured chord ruptured papillary muscle • Symptomatic patients with chronic severe MR as long as EF > 30% • Acute endocarditis with hemodynamic compromise, persistent sepsis, annular abscess, recurrent emboli • Asymptomatic patients with severe MR and EF 30-60%

  22. Mitral Regurgitation-Class IIa and IIb Indications • Patients with severe MR with class III-IV symptoms and EF < 30% and/or end-systolic dimension > 55 mm and if a repair is highly likely • There are 2 class IIb indications with asymptomatic patients with severe MR with EF > 60% who develop new onset atrial fibrillation and/or pulmonary hypertension (PAP > 50 mm Hg)

  23. Mitral Regurgitation-Asymptomatic • Asymptomatic patients with severe MR should be followed closely with ECHO every 6 months • If there is evidence of left ventricular dysfunction with a decreased EF < 60 %, patients should be referred for surgery • Preoperative EF important predictor of long term survival after mitral valve surgery

  24. Effect of preoperative EF • Long term postoperative prognosis is related to preoperative EF Circulation, 1995

  25. Mitral Regurgitation-Salient Points • In asymptomatic patients with severe mitral regurgitation ventricular function should be followed closely • If EF decreases to < 60% or left ventricular end systolic diameter dimension exceeds 40 mm patient should be referred for surgery • Mitral valve repair is the ideal procedure

  26. Prosthetic Valves • No “perfect” prosthetic valve • Bioprosthetic valves versus mechanical

  27. Prosthetic Valves porcine bovine pericardial mechanical

  28. Prosthetic Valves-Selection • Generally, if patient is > 65 a tissue valve is recommended • Due improvements in the manufacturing process tissue valves have increased durability demineralization to prevent calcification “zero pressure” tissue fixation • General trend to place tissue valves in younger patients • Ultimate decision is patient’s

  29. Prosthetic Valve Selection • Some tissue valves have demonstrated 85% 15 year structural free deterioration • Some evidence to suggest antiplatelet therapy may be sufficient anticoagulation in select patients with mechanical AVR (not a guideline) select cohort normal LV function normal sinus rhythym bileaflet mechanical valve ongoing clinical trails to determine efficiacy

  30. Early Anticoagulation in bioprosthetic valves • Historically “early” anticoagulation recommended in immediate postoperative period for tissue valves is warfarin for 3 months (AHA/ACC guidelines) • Expanding clinical evidence to support use of antiplatelet therapy alone after aortic tissue valve placement in early postoperative period unless there is some other indication for warfarin¹΄² JTCS,2005 JTCS,2010

  31. Percutaneous Therapy • TAVI (transcatheter aortic valve implantation) • Reserved for patients with severe aortic stenosis who are not surgical candidates for open procedure • Recently FDA approved • Likely will be regulated • Should involve societal (STS) oversights and database • Should be collaborative, multidisciplinary approach

  32. Percutaneous Aortic Valve • ? Long term durability • Aortic insufficiency • equivalent 1 year survival¹ • compared to open surgery • in some studies 1. NEJM, 2010

More Related